Click on the "Follow" button below and you'll get the latest news from Med Tech Gurus via email, mobile or you can read them on your personal news page on this site.
You can unsubscribe anytime you want easily.
You can also choose the topics or keywords that you're interested in, so you receive only what you want.
Med Tech Gurus title: Med Tech Gurus
Is this your feed? Claim it!
Is the future of MedTech innovation shifting away from devices—and toward manufacturing?
In this episode of Med Tech Gurus, we sit down with Mark Freitas, Managing Director and Life Sciences Leader at Alvarez & Marsal, to explore a major shift happening in MedTech: capital is moving away from traditional device acquisitions and toward advanced manufacturing platfor...
Cybersecurity in healthcare is no longer an IT issue—it's a patient safety issue.
In this episode of Med Tech Gurus, we sit down with Skip Sorrels, Field CTO and Chief Information Security Officer at Claroty, to explore how cyber threats are evolving from data breaches into full-scale clinical and operational disruptions.
With a unique background as both an ICU ...
Why do breakthrough medical technologies still fail to get adopted?
In this episode of Med Tech Gurus, we sit down with David Neale, Co-Founder and CEO of Argá MedTech, to explore what it really takes to bring a differentiated cardiac technology from concept to clinical adoption.
Argá is advancing next-generation pulsed field ablation (PFA) for the treatment of ...
What does it really mean to put the patient at the center of healthcare innovation?
In this episode of Med Tech Gurus, we sit down with Stephanie Hunter-Banks of Jazz Pharmaceuticals, a leader in medical learning, patient engagement, and rare disease advocacy. But what makes this conversation truly powerful is that Stephanie doesn't just study the patient journey—she l...
In rare disease, time isn't money—it's lives.
In this episode of Med Tech Gurus, we sit down with Dr. Rob Freishtat, physician-scientist, former President and Co-Founder of Uncommon Cures, and board member of the Foundation for mRNA Medicines, to explore how clinical trial design is being rewritten for rare and ultra-rare conditions.
Traditional randomized, plac...